[Market Focus] Abion Drops 19% on News of 80 Billion Won Paid-In Capital Increase

Abion is showing weakness in early trading.

As of 9:05 a.m. on September 1, Abion was trading at 4,795 won, a sharp drop of 19.14% (1,135 won) compared to the previous trading day.

The news of a large-scale capital increase appears to have dampened investor sentiment. Previously, on August 29, Abion announced that it had decided to carry out a rights offering with a subsequent public offering of forfeited shares to raise approximately 79 billion won for operating funds and debt repayment. A total of 20.6 million new common shares will be issued at 3,850 won per share.

Of the funds raised through the paid-in capital increase, Abion plans to allocate 61.56 billion won for operating funds and 11.75 billion won for debt repayment, respectively. On the same day, the company also decided to carry out a bonus issue, allocating 0.8 new shares for each existing common share.

Through its website, Abion stated, "Our top priority is to expand patient treatment opportunities and achieve sustainable growth through new drug development, but due to the nature of the research and development process, long-term funding needs and uncertainties are inevitable." The company added, "We have reviewed various capital-raising options to secure the funds necessary for research and development, and inevitably chose a paid-in capital increase to ensure the smooth progress of our R&D projects."

This content was produced with the assistance of AI translation services.